Alcon Inc (ALC) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Alcon Inc stock CHF 33.91, price CHF 61.30, that is 44.7% below the price, quality 67 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range CHF 48.75 – CHF 83.98 · fair‑value band CHF 23.68 – CHF 44.14 · the CHF 61.30 price screens above the CHF 33.91 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 6, 2026.
Follow Alcon in your weekly email
Every Wednesday you see whether Alcon is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care.
Show moreShow less
It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures.
The company's cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert.
In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure.
Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers.
The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Stock analysis
Alcon Inc (ALC) currently trades at CHF 61.30, while our model-based Fair Value estimate is CHF 33.91, 45% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of CHF 43.88 per share, and 1 of the 26 models we run sit above the CHF 61.30 price.
Bear case: the Asset-Based group reads lowest at CHF 4.27, and 25 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: CHF 23.68 (bear) to CHF 44.14 (bull), the price of CHF 61.30 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 67/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Alcon Inc reported revenue of $10.9B in FY2025 versus $8.3B in FY2021, a compound +7.1%/yr. Reported net income was $1.0B in FY2025, compounding +28.5%/yr from FY2021.
Key figures
Market cap CHF 30.0B Large · P/E ratio 58.4 · P/S ratio 3.38 · EPS (TTM) CHF 1.05 · Dividend yield 0.5% · Net margin 5.9% · Return on equity 2.9% · Return on assets (EBIT) 3.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (medium confidence).
What moves the price
The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.
The share trades about 8% below its 52-week high and 26% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −56% fair-value upside, at −45%, ALC screens cheaper than that median.
Fair Value models
BearCHF 23.68Fair Value CHF 33.91BullCHF 44.14
Price CHF 61.30 · Downside -44.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (CHF 0.6540 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.80/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+9.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.8%
Start year 2020 (pandemic). Over 10 years: +4.9% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.9%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+22.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+22.1%
Dividend (yield on the price)0.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.22.1% vs 12.6%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−7% → 13%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes about as much growth as the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+7.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +5.1% a year for the price and +2.1% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (95 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
AI conclusion: Eye care positioning and healthy margins provide moderate moat signals, yet these are offset by low return on equity and limited visibility into culture or ownership.
Main risk: Antitrust regulators could continue blocking bolt-on acquisitions such as the abandoned LENSAR deal, limiting Alcon’s ability to complete its surgical portfolio or reduce competitive overlap in laser cataract systems.
Bull case: Alcon could leverage its surgical retina expertise and the Neurotech platform to develop integrated cell-therapy solutions that differentiate it from pure device rivals and offset any acquisition constraints.
Bear case: Persistent regulatory blocks combined with faster rival product cycles could leave Alcon with gaps in its surgical offerings, slowing portfolio growth and pressuring prices in core cataract and retina procedures.
Alcon’s recent acquisition of Neurotech adds the first FDA-approved cell therapy for a rare retinal condition to its portfolio, drawing on its surgical retina expertise for faster commercialization. The move expands growth options in an underserved area yet is projected to dilute core earnings per share slightly in 2027 before turning positive. Will the longer-term contribution from this new therapy area exceed the short-term earnings headwind?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks
Beats the industry median on 5/15 measures
Overall it trails its industry peers.
Valuation
Quality Score67 · Above median
Fair Value upside−44.7% · Below median
Profitability
Return on equity (12 months)2.9% · Below median
Return on assets3.3% · Below median
Net margin (12 months)5.9% · Below median
Operating margin (12 months)14.6% · Above median
Growth and dividend
Revenue growth (quarter YoY)8.7% · Above median
Dividend yield (12 months)0.5% · Bottom 25%
Balance sheet
Debt / equity0.19× · Above median
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/E (12 months)58.4× · Priciest 25%
P/B1.67× · Cheaper than median
P/S (12 months)3.38× · Pricier than median
Price / free cash flow (fiscal year)20.3× · Cheaper than median
EV/EBITDA16.4× · Pricier than median
PEG1.25× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 25
FUTURE (revenue growth)44· sector 40
PAST (return on equity)12· sector 30
HEALTH (low debt)91· sector 96
DIVIDEND (yield)9· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Alcon Inc Fair Value". https://www.fairvalue-calculator.com/stock/ALC
Frequently asked questions
Is Alcon Inc (ALC) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of CHF 33.91 versus a price of CHF 61.30, about 45% lower (overvalued).
What is the fair value of ALC?
Our model-based fair value for Alcon Inc is CHF 33.91 (as of Nov 6, 2026), built from audited fundamentals. The current price: CHF 61.30.
What is the quality score of ALC?
Alcon Inc has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Alcon Inc (ALC)?
Our model-based price target is the fair value of CHF 33.91 (as of Nov 6, 2026) from 26 valuation models. Cautious scenario CHF 23.68, optimistic scenario CHF 44.14. It is a calculation from audited fundamentals, not an analyst target.
What is the Alcon Inc stock forecast for 2026?
Our models put fair value at CHF 33.91, about 45% lower versus a price of CHF 61.30 (overvalued). Cautious scenario CHF 23.68, optimistic scenario CHF 44.14. The calculation is refreshed regularly with new filings.
What is the revenue of Alcon Inc (ALC)?
Alcon Inc reported trailing-twelve-month revenue of about $10.9B (latest available figure, as of Nov 6, 2026).
Does Alcon Inc pay a dividend?
Alcon Inc currently shows a dividend yield of 0.46% relative to its recent price (as of Nov 6, 2026).
What growth is priced into Alcon Inc (ALC)?
For today's price to be fair in a discounted-cash-flow model, Alcon Inc would have to grow free cash flow by +7.6 % per year for five years (discount rate 8.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +9.8 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of ALC use?
Our models discount Alcon Inc at 8.4 %: a base by market capitalisation (large), damped by beta 0.73, country premium for Switzerland. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Alcon Inc that is +7.6 % per year a year over ten years, using the same discount rate (8.4 %) and the same formula as our fair value.
How much growth has Alcon Inc (ALC) delivered so far?
Over the past 5 years revenue at Alcon Inc grew +9.8 % a year. The price currently implies +7.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Alcon Inc (ALC) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Alcon Inc (+7.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Alcon Inc (ALC)?
The free-cash-flow yield on the price is 4.93 %: that much free cash flow Alcon Inc produces per unit of market value. When it exceeds the discount rate of our models (8.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Alcon Inc (ALC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Alcon Inc it is CHF 33.91 per share (as of Nov 6, 2026), against a price of CHF 61.30. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Alcon Inc stock overvalued or undervalued in 2026?
As of Nov 6, 2026, ALC trades above its calculated fair value: price CHF 61.30, fair value CHF 33.91, a gap of about −45% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALC?
No. The price is what the market pays today (CHF 61.30); the fair value is what the company's own numbers justify (CHF 33.91). For Alcon Inc the two are CHF 27.39 per share apart. That gap is exactly why we show both numbers side by side.
How much is Alcon Inc worth?
The market values Alcon Inc at about CHF 30.0B (market capitalisation, as of Nov 6, 2026). Per share that is CHF 61.30; our models calculate a fair value of CHF 33.91 per share.
What do the bullish and bearish scenarios say about ALC?
Our models span a range for Alcon Inc: cautious scenario CHF 23.68, base CHF 33.91, optimistic CHF 44.14 per share (as of Nov 6, 2026, price CHF 61.30). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ALC?
Alcon Inc trades at a price-to-earnings ratio of 58.4 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of CHF 33.91 is built from several models across several years. Other multiples: PEG 1.3, P/B 1.7, P/S 3.4, EV/EBITDA 16.4.
What is the PEG ratio of ALC?
The PEG ratio of Alcon Inc is 1.25 (P/E divided by earnings growth, as of Nov 6, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Alcon Inc (ALC)?
Balance-sheet figures for Alcon Inc (as of Nov 6, 2026): return on equity 2.9%, debt of 0.19 per unit of equity. They feed the Quality Score of 67/100, which measures business quality independently of the share price.
How far is ALC from its 52-week high?
Alcon Inc trades at CHF 61.30, about 8% below its 52-week high of CHF 66.74 and 26% above the low of CHF 48.75 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of CHF 33.91 is for.
Which stocks are comparable to Alcon Inc?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Alcon Inc stock attractive at the current price?
The data as of Nov 6, 2026: price CHF 61.30, calculated fair value CHF 33.91 (−45%), Quality Score 67/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ALC calculated?
We run Alcon Inc through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of CHF 33.91, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. Alcon Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Alcon Inc (ALC)?
The closing price on Nov 6, 2026 was CHF 61.30. Our model-based fair value is CHF 33.91, about 45% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Alcon Inc right now?
The price sits above even our optimistic bull case (CHF 44.14). The favourable scenario is already priced in. Solid but not exceptional quality (67/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (CHF 23.68 to CHF 44.14) leaves room in how you read the outcome.
Key figures of Alcon Inc
How large is the market capitalisation of Alcon Inc (ALC)?
The market capitalisation of Alcon Inc is CHF 30.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Alcon Inc (ALC)?
The price-to-sales ratio of Alcon Inc is 3.38 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Alcon Inc (ALC)?
Earnings per share at Alcon Inc are CHF 1.05 (price ÷ EPS = P/E 58.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Alcon Inc (ALC)?
The dividend yield of Alcon Inc is 0.5% (payout 26.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Alcon Inc (ALC)?
The net margin of Alcon Inc is 5.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Alcon Inc (ALC)?
The return on equity (ROE) of Alcon Inc is 2.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Alcon Inc (ALC)?
On an EBIT basis the return on assets of Alcon Inc is 3.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Alcon Inc (ALC)?
The operating margin of Alcon Inc is 14.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Alcon Inc (ALC)?
Revenue at Alcon Inc is growing +8.7% versus a year earlier (3y avg +7.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Alcon Inc (ALC)?
Earnings per share at Alcon Inc are growing −44.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Alcon Inc (ALC) carry?
The net debt of Alcon Inc is $4.1B (fiscal year 2025, ≈ 2.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Alcon Inc in the live analysis
One click puts Alcon Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 6, 2026